Cepton Unveils Vista®-X90, Sets New Standard for High Performance, Automotive-Grade Lidar
22.9.2020 15:00:00 EEST | Business Wire | Press release
Cepton Technologies, Inc., a leading provider of state-of-the-art, intelligent, lidar-based solutions, has announced details of its groundbreaking automotive-grade lidar sensor – the Vista®-X90, priced at less than $1000 for high volume automotive applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005088/en/
With a width of 120 mm, depth of 110 mm and a front-facing height of <45 mm, the compact, non-rotational Vista-X90 allows seamless vehicle integration. © 2020 Cepton Technologies.
The Vista-X90 is the newest addition to Cepton’s Vista-X automotive grade sensor family. It sets a new benchmark for high performance at low power in a compact form factor, and is ideally suited for advanced driver assistance systems (ADAS) and autonomous vehicles (AVs). Weighing less than 900 g, the Vista-X90 achieves up to 200 m range at 10% reflectivity with an outstanding angular resolution of 0.13° and state-of-the-art power consumption of <12W. The sensor supports frame rates of up to 40 Hz.
Optimized for ease of vehicle integration, the Vista-X90 has a licensable design architecture powered by Cepton’s patented Micro Motion Technology (MMT®) – a frictionless, mirrorless, rotation-free lidar architecture capable of high resolution and long range 3D imaging, while maximizing the sensor robustness and reliability to meet the stringent requirements of automotive applications.
Powered by Cepton’s next generation ASIC technology, the Vista-X90 is an ISO26262 ASIL-B sensor that supports AUTOSAR and over-the-air (OTA) functionality, with advanced capabilities for factory, extrinsic and dynamic calibration. With a width of 120 mm, depth of 110 mm and a front-facing height of <45 mm, Vista-X90 is compact and embeddable. Its 90° x 25° field of view, combined with its directional, non-rotational design allows seamless vehicle integration - such as in the fascia, behind the windshield or on the roof.
Built with easily available and inexpensive components using a highly manufacturable, modular and scalable architecture, the Vista-X90 is ideally suited for high volume production to bring truly cost-effective lidar solutions to ADAS and AV markets. Cepton has licensed its technology to the world’s largest automotive headlamp Tier 1, Koito, who has non-exclusive rights to manufacture and sell Cepton’s lidar technology for an automotive application, using key modules supplied by Cepton.
“We are excited to disrupt the industry with the Vista-X90, which is the most cost-effective, high-performance lidar in the world for automotive applications,” said Dr. Jun Pei, Cepton’s CEO. “Automotive lidars have historically had either low performance at acceptable cost or claimed high performance while being too expensive for many OEM programs. The Vista-X90 fundamentally changes the game by bridging that divide and delivering the optimal mix of performance, power, reliability and cost. This is an integral part of our plan to make lidar available as an essential safety device in every consumer vehicle in the world.”
The Vista-X90 is targeted for production in 2022 and beyond, and samples can be made available upon request.
To learn more about the Vista-X90 and Cepton’s automotive grade lidar capabilities, join Cepton at the upcoming Automotive Lidar 2020 conference next week, between September 22 – 24, 2020. Please visit our virtual booth page and sign up to hear Cepton’s Senior Director of Business Development, Mitch Hourtienne, discuss the Vista lidars in his talk “Importance of Tier 1 Collaboration for an Automotive ADAS Production Program” on September 23 at 11:15 am EST.
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as autonomous driving, ADAS, intelligent transportation systems (ITS), smart spaces and industrial robotics. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, UK, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005088/en/
Contact information
Faithy Li, Cepton Technologies, media@cepton.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom